May 23, 2023 11:29 AM EDT

Weight loss field expands as Pfizer's oral GLP-1 gathers comparisons to Novo's Wegovy in PhII data

Kyle LaHucik

Senior Reporter

Pfizer’s attempt to catch up in the weight loss market picked up steam on Monday with research showing the company’s GLP-1 agonist helped people with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Weight loss field expands as Pfizer's oral GLP-1 gathers comparisons to Novo's Wegovy in PhII data

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Supreme Court narrowly rejects Purdue bankruptcy plan, says it gives Sacklers too much protection

FDA rejects Daiichi Sankyo's HER3 ADC, a blow to quick approval plans for Merck partnership

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

What Coherus' $40M sale of its Humira biosimilar says about the crowded market

Grail pioneered multi-cancer tests. But the company’s rough public debut shows the industry could be in trouble

AbbVie buys Third Rock's Celsius for $250M to expand IBD pipeline

Weight loss field ex­pands as Pfiz­er's oral GLP-1 gath­ers com­par­isons to Novo's We­govy in PhII da­ta

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

Supreme Court nar­row­ly re­jects Pur­due bank­rupt­cy plan, says it gives Sack­lers too much pro­tec­tion

FDA re­jects Dai­ichi Sanky­o's HER3 ADC, a blow to quick ap­proval plans for Mer­ck part­ner­ship

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

What Co­herus' $40M sale of its Hu­mi­ra biosim­i­lar says about the crowd­ed mar­ket

Grail pi­o­neered mul­ti-can­cer tests. But the com­pa­ny’s rough pub­lic de­but shows the in­dus­try could be in trou­ble

Ab­b­Vie buys Third Rock­'s Cel­sius for $250M to ex­pand IBD pipeline

Weight loss field expands as Pfizer's oral GLP-1 gathers comparisons to Novo's Wegovy in PhII data

Supreme Court narrowly rejects Purdue bankruptcy plan, says it gives Sacklers too much protection

FDA rejects Daiichi Sankyo's HER3 ADC, a blow to quick approval plans for Merck partnership

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

What Coherus' $40M sale of its Humira biosimilar says about the crowded market

Grail pioneered multi-cancer tests. But the company’s rough public debut shows the industry could be in trouble

AbbVie buys Third Rock's Celsius for $250M to expand IBD pipeline